In the KEYNOTE-189 patients with nonsquamous NSCLC without sensitizing EGFR or ALK mutations received 4 courses of platinum-Pemetrexed plus Pembrolizumab followed by maintenance with Pemetrexed plus Pembrolizumab in responders and in those with stable disease (up to 35 cycles, ∼2 years). The gene discussed is ALK; the disease is non-small cell lung carcinoma.